A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC).

被引：1
|
作者：
Funt, Samuel Aaron
Jatwani, Karan
Makris, Michelle
Regazzi, Ashley Marie
Lee, Chung-Han
Teo, Min Yuen
McHugh, Deaglan Joseph
Mccoy, Asia S.
Hettich, Grace
Wong, Phillip
Abu-Akeel, Moshen
Wolchok, Jedd D.
Merghoub, Taha
Al-Ahmadie, Hikmat
Ostrovnaya, Irina
Chaim, Joshua
Durack, Jeremy C.
Iyer, Gopa
Bajorin, Dean F.
Rosenberg, Jonathan E.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Mt Sinai St Lukes & West Hosp, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.4559
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4559
引用
收藏
页数：2
相关论文
共 50 条
  • [41] EFFECTIVENESS AND SAFETY OF FIRST-LINE BEVACIZUMAB PLUS FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Pinto, Ana Catarina
    Teixeira, Margarida
    Bonito, Nuno
    Jacinto, Paula
    Ribeiro, Joao
    Gervasio, Helena
    ANNALS OF ONCOLOGY, 2011, 22 : v98 - v98
  • [42] Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study
    Neri, Bruno
    Vannini, Laura
    Giordano, Clara
    Grifoni, Raffaella
    Pantaleo, Pietro
    Baldazzi, Valentina
    Crisci, Alfonso
    Lapini, Alberto
    Raugei, Andrea
    Carini, Marco
    ANTI-CANCER DRUGS, 2007, 18 (10) : 1207 - 1211
  • [43] Early switching to pembrolizumab (Pe) during first-line platinum-based chemotherapy (PCT) in patients (pts) with metastatic urothelial carcinoma (mUC).
    Endo, Yuki
    Kimura, Go
    Akatsuka, Jun
    Takeda, Hayato
    Yanagi, Masato
    Mikami, Hikaru
    Hasegawa, Hiroya
    Taniuchi, Mami
    Katsu, Akifumi
    Funato, Ryota
    Toyama, Yuka
    Kondo, Yukihiro
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [44] Atezolizumab as first-line therapy in elderly patients with NSCLC
    Franke, Katharina
    PNEUMOLOGIE, 2024, 78 (05): : 287 - 287
  • [45] Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy
    Galsky, Matt D.
    Moshier, Erin L.
    Krege, Susanne
    Lin, Chia-Chi
    Hahn, Noah M.
    Ecke, Thorsten
    Sonpavde, Guru
    Pond, Gregory Russell
    Godbold, James H.
    Oh, William K.
    Bamias, Aristotelis
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [46] Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma
    Urakami, Shinji
    Fujii, Yasuhisa
    Yamamoto, Shinya
    Yuasa, Takeshi
    Kitsukawa, Shinichi
    Sakura, Mizuaki
    Yano, Akihiro
    Saito, Kazutaka
    Masuda, Hitoshi
    Yonese, Junji
    Fukui, Iwao
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (01) : 35.e1 - 35.e7
  • [47] Atezolizumab as first-line therapy in elderly patients with NSCLC
    Franke, Katharina
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (03) : 75 - 75
  • [48] Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study
    L. Dogliotti
    S. Danese
    A. Berruti
    P. Zola
    T. Buniva
    A. Bottini
    G. Richiardi
    G. Moro
    A. Farris
    M. G. Baù
    G. Porcile
    Cancer Chemotherapy and Pharmacology, 1998, 41 : 333 - 338
  • [49] Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study
    Dogliotti, L
    Danese, S
    Berruti, A
    Zola, P
    Buniva, T
    Bottini, A
    Richiardi, G
    Moro, G
    Farris, A
    Bau, MG
    Porcile, G
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 41 (04) : 333 - 338
  • [50] Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer
    Possinger, K
    Kaufmann, M
    Coleman, R
    Stuart, NSA
    Helsing, M
    Ohnmacht, U
    Arning, M
    ANTI-CANCER DRUGS, 1999, 10 (02) : 155 - 162
12345